ArticleMikrochimica acta2025
Core-shell ZIF-8@Au labels for high-sensitivity lateral flow assays via thiol-functionalization and seed-mediated growth.
Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
ZIF-8-core/Au-shell (ZIF-8@Au) nanoparticles were fabricated through a two-step strategy involving thiol-modification of ZIF-8 substrates and subsequent Au shell growth via seed-mediated approach, and the ZIF-8@Au nanoparticles were applied to the screening of clostridium difficile infection (CDI). Through regulating dosage of thiol-modifier, we established a surface functionalization protocol that introduced tunable thiol groups onto ZIF-8 particles while preserving their pristine morphology and crystallinity. Subsequent refinement of Au coating parameters enabled the construction of ZIF-8@Au core-shell nanostructures via seed-mediated growth. The resulting ZIF-8@Au nanoparticles were successfully applied to detect biomarkers of CDI, including toxin A, toxin B, and glutamate dehydrogenase (GDH), with sensitivities of 7 pg/mL, 115 pg/mL, and 27 pg/mL, respectively. These results demonstrate the promising potential of this nanoparticle-based platform for lateral flow assays.
Indexed as
Identifiers
41286372What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.